Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231714 | 0.83 | HPGD (0.53) | CES2CES1HPGDALDH1A1POLB | |
| SCHEMBL473969 | 0.83 | HPGD (0.53) | CES2CES1HPGDALDH1A1POLB | |
| SCHEMBL16957960 | 0.83 | CES2 (0.40) | CES2CES1KEAP1HPGDCLCN2 | |
| SCHEMBL8232600 | 0.82 | CES2 (0.42) | CES2CES1KEAP1HPGDCLCN2 | |
| SCHEMBL477556 | 0.81 | CES2 (0.48) | CES2CES1KEAP1HPGDCLCN2 | |
| SCHEMBL16961563 | 0.81 | KEAP1 (0.39) | CES2CES1KEAP1HPGDCLCN2 | |
| SCHEMBL786240 | 0.81 | ALDH1A1 (0.63) | CES2CES1KEAP1CLCN2ALDH1A1 | |
| SCHEMBL1785686 | 0.79 | ALDH1A1 (0.50) | CES2CES1KEAP1HPGDALDH1A1 | |
| SCHEMBL30954398 | 0.79 | CES2 (0.47) | CES2CES1KEAP1HPGDCLCN2 | |
| SCHEMBL7985019 | 0.79 | SMN1; SMN2 (0.54) | CES2CES1HPGDCLCN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151930-A1 | PI3K INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-115260156-A | Compounds as JAK2 inhibitors and uses thereof | 华东理工大学 | 2022-11-01 | — | — | CN | disclosed |
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3782993-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | East China University of Science and Technology (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019196937-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
| US-6995159-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | disclosed |
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-02-10 | — | — | US | disclosed |
| US-6825198-B2 | FOR THERAPY OF SEXUAL DISORDER | PFIZER INC | 2004-11-30 | — | — | US | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-4997840-A | Quinolone sulphonates having antihypertensive activity | THE BOOTS COMPANY, PLC (GB) | 1991-03-05 | — | — | US | disclosed |
| EP-0330340-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032809-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885KEAP1 4452/4885 |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885KEAP1 4452/4885 |
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | JAK2, JAK1, JAK3 | CES2 4726/4885CES1 3705/4885KEAP1 608/4885 |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | CES2 366/4885CES1 1255/4885KEAP1 4313/4885 |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | CES2 364/4885CES1 1549/4885KEAP1 4452/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | CES2 366/4885CES1 1255/4885KEAP1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.